Esmolol Dosing for Ventricular Tachycardia
For certain forms of polymorphic VT (associated with acute ischemia, familial LQTS, or catecholaminergic VT), use esmolol with an IV loading dose of 500 mcg/kg (0.5 mg/kg) over 1 minute, followed by an infusion of 50 mcg/kg per minute (0.05 mg/kg per minute). If response is inadequate, give a second loading bolus of 0.5 mg/kg over 1 minute and increase the maintenance infusion to 100 mcg/kg per minute, continuing to titrate up to a maximum of 300 mcg/kg per minute as needed 1.
Critical Context: Esmolol is NOT First-Line for Most VT
Esmolol is specifically indicated only for select polymorphic VT subtypes—NOT for hemodynamically stable monomorphic VT. The 2010 AHA ACLS guidelines clearly distinguish between VT types 1:
For Hemodynamically Stable Monomorphic VT (Standard VT):
- First-line options: Procainamide (20-50 mg/min), Amiodarone (150 mg over 10 minutes), Sotalol, or Lidocaine
- Esmolol is NOT listed as a treatment option for this common presentation
For Polymorphic VT - Esmolol's Specific Role:
Esmolol is reserved for polymorphic VT associated with:
- Acute myocardial ischemia
- Familial long QT syndrome (LQTS)
- Catecholaminergic polymorphic VT
These conditions involve excessive catecholaminergic drive where beta-blockade addresses the underlying mechanism 1.
Dosing Algorithm
Step 1: Loading Dose
- 500 mcg/kg (0.5 mg/kg) IV push over 1 minute
Step 2: Initial Maintenance Infusion
- Start at 50 mcg/kg per minute
Step 3: Titration (if inadequate response)
- Give second loading bolus: 0.5 mg/kg over 1 minute
- Increase maintenance to 100 mcg/kg per minute
- Continue this pattern (repeat bolus + increase infusion by 50 mcg/kg/min increments)
- Maximum infusion rate: 300 mcg/kg per minute 1, 2
Step 4: Monitoring
- Esmolol has a 2-9 minute half-life, allowing rapid titration 1
- Steady-state achieved in approximately 30 minutes without loading doses 2
Critical Safety Considerations
Absolute Contraindications:
- Decompensated heart failure
- Asthma or obstructive airway disease
- 2nd or 3rd degree AV block (without pacemaker)
- Bradycardia
- Pre-excited atrial fibrillation/flutter 1, 3
Common Adverse Effects:
- Hypotension (most common—occurs in 20-50% of patients) 1, 2
- Bradycardia
- Precipitation of heart failure
Reversal Strategy: Due to esmolol's ultrashort half-life, simply reducing or stopping the infusion rapidly reverses effects within 10-30 minutes 1, 2. Have esmolol 10 mg/mL dilution (0.5 mg/kg dose) available for immediate reversal if needed 4.
Emerging Evidence for Refractory VF/VT
Recent research suggests potential benefit in refractory ventricular fibrillation (≥3 failed defibrillation attempts), though this remains investigational:
- One retrospective study showed 56% sustained ROSC with esmolol vs. 16% in controls for refractory VF 5
- IHCA patients with refractory shockable rhythms showed 79% sustained ROSC and 59% survival to discharge when esmolol was added 6
- Esmolol may counteract epinephrine's negative effects during resuscitation 7
However, this is NOT guideline-recommended therapy. Standard ACLS protocols with amiodarone or lidocaine remain first-line for VF/pulseless VT 1.
Common Pitfalls
- Using esmolol for monomorphic VT: This is inappropriate—use procainamide or amiodarone instead
- Inadequate dose titration: Many clinicians stop at 50-100 mcg/kg/min when higher doses (up to 300 mcg/kg/min) may be needed
- Forgetting the loading dose: Without it, therapeutic effect takes 30 minutes to achieve 2
- Using in structural heart disease without caution: Negative inotropic effects can precipitate heart failure 1